TCGA-D8-A27W-01A-11R-A16F-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 12
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.560
- MYC_TARGETS_V1+0.430
- E2F_TARGETS+0.390
- UNFOLDED_PROTEIN_RESPONSE+0.390
- MTORC1_SIGNALING+0.380
- G2M_CHECKPOINT+0.360
- OXIDATIVE_PHOSPHORYLATION+0.350
- PROTEIN_SECRETION+0.350
- PANCREAS_BETA_CELLS+0.330
- DNA_REPAIR+0.220
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.390
- IL6_JAK_STAT3_SIGNALING-0.300
- INFLAMMATORY_RESPONSE-0.270
- COAGULATION-0.220
- TGF_BETA_SIGNALING-0.190
- APICAL_SURFACE-0.170
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.170
- INTERFERON_GAMMA_RESPONSE-0.160
- KRAS_SIGNALING_UP-0.150
- APOPTOSIS-0.140
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_M84H3KXA | Med | Medulloblastoma | 0.838 |
| 2 | BS_YETBN0RQ | Med | Medulloblastoma | 0.829 |
| 3 | MDT-AP-2956 | Med | Medulloblastoma | 0.827 |
| 4 | TCGA-CN-4730-01A-01R-1436-07 | — | — | 0.817 |
| 5 | MNG1063 | — | — | 0.815 |
| 6 | 9f6a2480-748d-414b-be0b-36be34c24037 | — | — | 0.811 |
| 7 | MNG432 | — | — | 0.808 |
| 8 | MDT-AP-0322 | Med | Medulloblastoma | 0.807 |
| 9 | TCGA-E9-A1RB-01A-11R-A157-07 | — | C | 0.804 |
| 10 | TCGA-66-2727-01A-01R-0980-07 | — | cohortSQ2 | 0.802 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.560 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.430 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.390 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.390 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.380 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.360 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.350 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.350 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.330 | Cobimetinib | — uncovered |
| DNA_REPAIR | 0.220 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.190 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.180 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.180 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |
| PEROXISOME | 0.160 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.120 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.100 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.090 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.070 | Inavolisib | — uncovered |